Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

This study has been withdrawn prior to enrollment.
(Gemcitabine is not the first choice for most pancreatic cancer patients nowdays)
Sponsor:
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital
ClinicalTrials.gov Identifier:
NCT01598584
First received: May 5, 2012
Last updated: September 24, 2015
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)